newsfilter
← Latest News
GlobeNewswire·

CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

NEWARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today